JP2023553384A5 - - Google Patents

Info

Publication number
JP2023553384A5
JP2023553384A5 JP2023533306A JP2023533306A JP2023553384A5 JP 2023553384 A5 JP2023553384 A5 JP 2023553384A5 JP 2023533306 A JP2023533306 A JP 2023533306A JP 2023533306 A JP2023533306 A JP 2023533306A JP 2023553384 A5 JP2023553384 A5 JP 2023553384A5
Authority
JP
Japan
Prior art keywords
linker
molecule
molecule according
extension portion
life extension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023533306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553384A (ja
JP7886869B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061587 external-priority patent/WO2022120033A1/en
Publication of JP2023553384A publication Critical patent/JP2023553384A/ja
Publication of JP2023553384A5 publication Critical patent/JP2023553384A5/ja
Application granted granted Critical
Publication of JP7886869B2 publication Critical patent/JP7886869B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023533306A 2020-12-03 2021-12-02 複数の結合ドメインを有する免疫グロブリン構築物 Active JP7886869B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121166P 2020-12-03 2020-12-03
US63/121,166 2020-12-03
PCT/US2021/061587 WO2022120033A1 (en) 2020-12-03 2021-12-02 Immunoglobuline constructs with multiple binding domains

Publications (3)

Publication Number Publication Date
JP2023553384A JP2023553384A (ja) 2023-12-21
JP2023553384A5 true JP2023553384A5 (cg-RX-API-DMAC7.html) 2024-12-09
JP7886869B2 JP7886869B2 (ja) 2026-07-08

Family

ID=79170974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533306A Active JP7886869B2 (ja) 2020-12-03 2021-12-02 複数の結合ドメインを有する免疫グロブリン構築物

Country Status (10)

Country Link
US (1) US20250277024A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255931A1 (cg-RX-API-DMAC7.html)
JP (1) JP7886869B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230117397A (cg-RX-API-DMAC7.html)
CN (1) CN116783217A (cg-RX-API-DMAC7.html)
AU (1) AU2021393456A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203468A1 (cg-RX-API-DMAC7.html)
IL (1) IL303205A (cg-RX-API-DMAC7.html)
MX (1) MX2023006573A (cg-RX-API-DMAC7.html)
WO (1) WO2022120033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023268600A1 (en) * 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2026152120A2 (en) 2025-01-13 2026-07-16 HCW Biologics, Inc. Chimeric polypeptides and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE19650370A1 (de) 1996-12-05 1998-06-10 Basf Ag Flammwidrige thermoplastische Formmassen auf der Basis von Polyarylenethern
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
CA2560889A1 (en) 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR100609578B1 (ko) 2004-12-28 2006-08-08 주식회사 하이닉스반도체 플래쉬 메모리소자의 플로팅 게이트전극 형성방법
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Erasmus大學醫學中心 對偶基因排除
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014151910A1 (en) * 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
EP3774914A2 (en) * 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs

Similar Documents

Publication Publication Date Title
KR102642385B1 (ko) 표적화된 키메라 단백질 및 이의 용도
US20240368277A1 (en) SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF
KR102877915B1 (ko) 섬유아세포 결합제 및 이의 용도
US12583898B2 (en) Therapeutic interferon alpha 1 proteins
JP2022179773A (ja) 標的化改変型インターフェロン及びその使用
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2016513467A5 (cg-RX-API-DMAC7.html)
WO2017194782A2 (en) Therapeutic targeting of non-cellular structures
JP2022546454A5 (cg-RX-API-DMAC7.html)
US20240199714A1 (en) Il-2 based constructs
JP2024116283A5 (cg-RX-API-DMAC7.html)
JP2021512151A5 (cg-RX-API-DMAC7.html)
US20220119472A1 (en) Modulation of dendritic cell lineages
JP2025128343A5 (cg-RX-API-DMAC7.html)
JP2022550345A (ja) Pd-l1標的化キメラタンパク質及びその使用
JP2022535060A5 (cg-RX-API-DMAC7.html)
JP2022535061A5 (cg-RX-API-DMAC7.html)
US20220378925A1 (en) Conjugated chimeric proteins
TH2101001911A (th) โมเลกุลที่เชื่อมต่อแอนติเจนชนิดไบสเปซิฟิก ซึ่งประกอบรวมด้วยโคลนสารต้าน fap212